Top

Infectious Agents and Cancer

Published in:

Open Access 01-12-2024 | Hepatitis B | Research

Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy

Authors: Lijie Zhang, Yiming Liu, Songlin Song, Joyman Makamure, Heshui Shi, Chuansheng Zheng, Bin Liang

Published in: Infectious Agents and Cancer | Issue 1/2024

Abstract

Background

Hepatitis B virus (HBV) reactivation (HBVr) is a major concern for hepatocellular carcinoma (HCC) patients undergoing hepatic arterial infusion chemotherapy (HAIC) using mFOLFOX6 regimen. There is insufficient evidence to support the routine use of HAIC combined with immunotherapy in HCC patients with HBVr. The aim of this study was to examine the adverse events (AEs) related to HBVr in HCC patients after HAIC, with or without immunotherapy, and to assess the effectiveness of antiviral prophylaxis for HBVr.

Methods

Medical records of HCC patients receiving HAIC combined with and without immunotherapy between January 2021 and June 2023 were reviewed. The patients were divided into two groups based on whether they received immunotherapy or not.

Results

Out of the 106 patients, 32 (30.2%) developed HBVr. Among these, 23 eligible patients with HBVr were included, with 14 patients (61%) receiving immunotherapy and nine patients (39%) not receiving immunotherapy. Prior to HAIC treatment, four patients in each group had detectable HBV DNA with median titre of 3.66 × 10² IU/ml (patients with immunotherapy) and 1.98 × 10² IU/ml (patients without immunotherapy), respectively. Fifteen patients did not show detectable HBV DNA. At HBVr occurrence, the median HBV DNA level was 6.95 × 10² IU/ml for all patients, 4.82 × 10² IU/ml in patients receiving immunotherapy and 1.3 × 10³ IU/ml in patients not receiving immunotherapy. Grade 3 hepatitis developed in 12 cases of all patients (12/23, 48%), including five patients with immunotherapy (56%) and seven patients without immunotherapy (78%). At the 3-month follow-up, HBV DNA was detected in 10 patients, with a median HBV DNA level of 2.05 × 10² IU/ml (range, 1.5 × 10²– 3.55 × 10² IU/ml) in patients (7/10) with immunotherapy and 4.28 × 10² IU/ml (range, 1.15 × 10²– 5.88 × 10² IU/ml) in patients (3/10) without immunotherapy. Intensified antiviral treatment was administered to all patients. No HBVr-related fatal events occurred.

Conclusion

HBVr can occur after HAIC combined with or without immunotherapy. The degree of liver damage did not differ significantly in patients treated with or without immunotherapy. Intensified antiviral treatment was found to be crucial for HCC patients with HBVr.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3.CrossRefPubMed

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the study of the liver. EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.CrossRef

Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. Guidelines for the diagnosis and treatment of primary Liver Cancer (2022 Edition). Liver Cancer. 2023;12:405–44. https://doi.org/10.1159/000530495.CrossRefPubMedPubMedCentral

Voican CS, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol. 2016;27(12):2172–84. https://doi.org/10.1093/annonc/mdw414.CrossRefPubMed

Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl). https://doi.org/10.1002/hep.22945. S156-65.

Loomba R, Liang TJ. Hepatitis B Reactivation Associated with Immune suppressive and biological modifier therapies: current concepts, Management Strategies, and future directions. Gastroenterology. 2017;152(6):1297–309. https://doi.org/10.1053/j.gastro.2017.02.009.CrossRefPubMed

Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670–89. https://doi.org/10.1016/j.jhep.2022.07.003.CrossRefPubMed

Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: a systematic review. Hepatology. 2022;75(5):1257–74. https://doi.org/10.1002/hep.32241.CrossRefPubMed

10.

Dan JQ, Zhang YJ, Huang JT, Chen MS, Gao HJ, Peng ZW, et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2013;39(8):865–72. https://doi.org/10.1016/j.ejso.2013.03.020.CrossRefPubMed

11.

Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol. 2018;3:89. https://doi.org/10.21037/tgh.2018.10.16.CrossRefPubMedPubMedCentral

12.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8. https://doi.org/10.1186/s40425-018-0316-z.CrossRefPubMedPubMedCentral

13.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745.CrossRefPubMed

14.

Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22(2):219–37. https://doi.org/10.3350/cmh.2016.0024.CrossRefPubMedPubMedCentral

15.

Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519–28. https://doi.org/10.7326/0003-4819-148-7-200804010-00008.CrossRefPubMedPubMedCentral

16.

Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010;107(2):798–802. https://doi.org/10.1073/pnas.0913498107.CrossRefPubMed

17.

Cho H, Kang H, Kim CW, Kim HY, Jang JW, Yoon SK, et al. Phenotypic characteristics of PD-1 and CTLA-4 expression in symptomatic Acute Hepatitis A. Gut Liver. 2016;10(2):288–94. https://doi.org/10.5009/gnl14368.CrossRefPubMed

18.

Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology. 2014;146(5):1193–207. https://doi.org/10.1053/j.gastro.2013.12.036.CrossRefPubMed

19.

Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, et al. PD-L1 negatively regulates CD4 + CD25 + Foxp3 + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119(3):551–64. https://doi.org/10.1172/JCI36604.CrossRefPubMedPubMedCentral

20.

Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129(15):2186–97. https://doi.org/10.1182/blood-2016-09-741629.CrossRefPubMedPubMedCentral

21.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. https://doi.org/10.1002/hep.29086.CrossRefPubMed

22.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. https://doi.org/10.1016/j.jhep.2017.03.021.CrossRef

23.

Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019;7(1):322. https://doi.org/10.1186/s40425-019-0808-5.CrossRefPubMedPubMedCentral

24.

Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221– 44.e3. https://doi.org/10.1053/j.gastro.2014.10.038.

25.

Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11. https://doi.org/10.1200/JCO.2008.18.0182.CrossRefPubMed

26.

Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–30. https://doi.org/10.1001/jama.2014.15704.CrossRefPubMed

27.

National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

28.

Araujo-Neto JM, Guimarães GS, Fernandes FF, Soares MA, Hepatitis B, Surface Antibody. (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: two prospective studies. Viruses. 2022;14(8):1780. https://doi.org/10.3390/v14081780.CrossRefPubMedPubMedCentral

29.

Yu Y, Zhang Y, Dai Y, Sun Q, Jiang C, Xu X, et al. Analysis of S gene characteristic sequences and changes in properties of protein expression in HBV ASCs with low-level HBsAg. Front Med (Lausanne). 2022;9:948842. https://doi.org/10.3389/fmed.2022.948842.CrossRefPubMed

30.

Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, et al. Effects of antiviral therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma patients undergoing hepatic artery infusion Chemotherapy. Front Oncol. 2021;10:582504. https://doi.org/10.3389/fonc.2020.582504.CrossRefPubMedPubMedCentral

31.

Yoo S, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, et al. Risk of Hepatitis B Virus Reactivation in patients treated with immunotherapy for anti-cancer treatment. Clin Gastroenterol Hepatol. 2022;20(4):898–907. https://doi.org/10.1016/j.cgh.2021.06.019.CrossRefPubMed

32.

Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2020;8(2):e001072. https://doi.org/10.1136/jitc-2020-001072.CrossRefPubMedPubMedCentral

33.

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83. https://doi.org/10.1002/hep.28156.CrossRefPubMed

34.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. https://doi.org/10.1002/hep.29800.CrossRefPubMed

35.

Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L, et al. Sorafenib Plus hepatic arterial infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor thrombosis: a Randomized Trial. Radiology. 2022;303(2):455–64. https://doi.org/10.1148/radiol.211545.CrossRefPubMed

Title: Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy
Authors: Lijie Zhang
Yiming Liu
Songlin Song
Joyman Makamure
Heshui Shi
Chuansheng Zheng
Bin Liang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Hepatitis B
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Cytostatic Therapy
Hepatitis
Entecavir
Published in: Infectious Agents and Cancer / Issue 1/2024
Electronic ISSN: 1750-9378
DOI: https://doi.org/10.1186/s13027-024-00574-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Nelfinavir inhibition of Kaposi’s sarcoma-associated herpesvirus protein expression and capsid assembly

No detectable truncating mutations in large T antigen (LT-Ag) sequence of Merkel cell polyomavirus (MCPyV) DNA obtained from porocarcinomas

Undifferentiated carcinoma of the liver with osteoclast-like giant cells: a case report and literature review

A systematic review of endometrial cancer clinical research in Africa

The global burden of cervical cancer requiring surgery: database estimates

Keynote webinar | Spotlight on antibody–drug conjugates in cancer